Abstract | OBJECTIVE: RESULTS: In 46 patients the frequency and the duration of seizures was significantly reduced (p < 0.001) as well as the number of convulsive status at a median of three-year follow-up. Ten patients were dramatically improved ( seizures significantly decreased in number [p = 0.002] and duration [p = 0.002] and status epilepticus disappeared), 20 were moderately improved ( seizures significantly decreased in duration [p = 0.001] and status were less numerous), four had no response and efficacy was non evaluable in 12 mainly because of adverse events. Efficacy was better in the youngest patients. The most frequent adverse events were loss of appetite and loss of weight. They could be so severe in patients over 12 years of age that the stiripentol dosage could not be increased to 50 mg kg-1 j-1. CONCLUSION:
|
Authors | T Nguyen Thanh, C Chiron, G Dellatolas, E Rey, G Pons, J Vincent, O Dulac |
Journal | Archives de pediatrie : organe officiel de la Societe francaise de pediatrie
(Arch Pediatr)
Vol. 9
Issue 11
Pg. 1120-7
(Nov 2002)
ISSN: 0929-693X [Print] France |
Vernacular Title | Efficacité et tolérance à long terme du stiripentol dans le traitement de l'épilepsie myoclonique sévère du nourrisson (syndrome de Dravet). |
PMID | 12503502
(Publication Type: Clinical Trial, Controlled Clinical Trial, Journal Article)
|
Chemical References |
- Anti-Anxiety Agents
- Anticonvulsants
- Dioxolanes
- Benzodiazepines
- Clobazam
- Valproic Acid
- stiripentol
|
Topics |
- Anti-Anxiety Agents
(therapeutic use)
- Anticonvulsants
(administration & dosage, adverse effects, pharmacology)
- Benzodiazepines
- Child, Preschool
- Clobazam
- Dioxolanes
(administration & dosage, adverse effects, pharmacology)
- Epilepsies, Myoclonic
(drug therapy, pathology)
- Female
- Humans
- Infant
- Male
- Severity of Illness Index
- Treatment Outcome
- Valproic Acid
(therapeutic use)
|